Amira Pharmaceuticals Announces Appointment of First Chief Executive Officer
Amira Pharmaceuticals announced that the company has appointed Robert F. Baltera, Jr., as the company's first chief executive officer, effective immediately.
Before becoming Amira's CEO, Baltera held a number of senior management positions at Amgen, most recently as vice president of corporate and contract manufacturing. A scientist by training, Baltera joined Amgen at the beginning of his career as a research associate but quickly moved to the operations side of the business, working in finance, product development and commercial operations. He successfully used that collective experience to serve as team leader responsible for the approval of Kineret(TM) in rheumatoid arthritis, a highlight of his many accomplishments while at Amgen.
Baltera has a master's of business administration from the Anderson School at UCLA. He earned his bachelor's degree in microbiology and a master's degree in genetics from The Pennsylvania State University.
Organizations
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.